PT1223971E - Composicoes e metodos para prevencao e tratamento da rejeicao de transplante - Google Patents

Composicoes e metodos para prevencao e tratamento da rejeicao de transplante

Info

Publication number: PT1223971E
Authority: PT; Portugal
Prior art keywords: compositions; methods; transplant rejection; treatment; prevention
Prior art date: 1999-10-27

Application number

PT00972507T

Other languages

English (en)

Inventor

Alexandra Lucas

Grant D Mcfadden

Robert Zhong

Original Assignee

Alexandra Lucas

Grant D Mcfadden

Robert Zhong

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-27

Filing date

2000-10-27

Publication date

2005-10-31

2000-10-27 Application filed by Alexandra Lucas, Grant D Mcfadden, Robert Zhong filed Critical Alexandra Lucas

2005-10-31 Publication of PT1223971E publication Critical patent/PT1223971E/pt

Links

206010052779 Transplant rejections Diseases 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
230000002265 prevention Effects 0.000 title 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
229930105110 Cyclosporin A Natural products 0.000 abstract 1
108010036949 Cyclosporine Proteins 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
101710181917 Serine proteinase inhibitor 1 Proteins 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
230000003409 anti-rejection Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
229960001265 ciclosporin Drugs 0.000 abstract 1
229930182912 cyclosporin Natural products 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Transplantation (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Fertilizers (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PT00972507T 1999-10-27 2000-10-27 Composicoes e metodos para prevencao e tratamento da rejeicao de transplante PT1223971E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US16164399P	1999-10-27	1999-10-27

Publications (1)

Publication Number	Publication Date
PT1223971E true PT1223971E (pt)	2005-10-31

Family

ID=22582094

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT00972507T PT1223971E (pt)	1999-10-27	2000-10-27	Composicoes e metodos para prevencao e tratamento da rejeicao de transplante

Country Status (10)

Country	Link
US (2)	US7514405B2 (pt)
EP (1)	EP1223971B1 (pt)
JP (1)	JP2003512436A (pt)
AT (1)	ATE297217T1 (pt)
AU (1)	AU1123001A (pt)
CA (1)	CA2385312C (pt)
DE (1)	DE60020727T2 (pt)
ES (1)	ES2243314T3 (pt)
PT (1)	PT1223971E (pt)
WO (1)	WO2001030379A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60020727T2 (de)	1999-10-27	2006-05-04	Robert London Zhong	Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
AU2001291579B2 (en) *	2000-09-29	2006-08-31	Viron Therapeutics Inc.	Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
WO2004039391A1 (en) *	2002-11-01	2004-05-13	Lucas Alexandra R	Viral serpin regulation of inflamation
US7285530B2 (en)	2004-10-21	2007-10-23	Viron Therapeutics, Inc.	Use of SERP-1 as an antiplatelet agent
MX2010012576A (es)	2008-05-23	2011-04-05	Argos Therapeutics Inc	Nuevos polipeptidos cd83 solubles, formulaciones y metodos de uso.
EP2477640A4 (en) *	2009-09-16	2014-02-26	Viron Therapeutics Inc	METHOD FOR TREATING A PATIENT WITH A HEART STENT IMPLANT
EP2978442B1 (en) *	2013-03-29	2020-03-18	The Regents of the University of Colorado, a body corporate	Alpha 1 antitrypsin of use for preparing a subject for transplant
WO2016154041A1 (en) *	2015-03-20	2016-09-29	University Of Florida Research Foundation Incorporated	Serpin reactive center loop peptides and methods of use
US10653760B2 (en)	2015-07-07	2020-05-19	University Of Florida Research Foundation, Incorporated	Compositions and methods for reducing organ rejection by reducing heparan sulfate in donor transplants
EP3534960A4 (en)	2016-11-07	2020-05-13	Coimmune, Inc.	SPECIFIC ANTIBODIES MODULATING AND USING THE TLR-4 SIGNALING
US12296066B2 (en) *	2018-05-18	2025-05-13	Arizona Board Of Regents On Behalf Of Arizona State University	Methods of wound healing with Serp-1 polypeptides

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5206017A (en)	1986-06-03	1993-04-27	Incyte Pharmaceuticals, Inc.	Use of protease nexin-I as an antiinflammatory
DE3829523A1 (de)	1988-08-31	1990-03-01	Behringwerke Ag	Verwendung von plasminogen-aktivator-inhibitor (pai-2) zur immunsuppression
GB9007971D0 (en) *	1990-04-09	1990-06-06	Imutran Ltd	Pharmaceutical formulations
ATE146970T1 (de)	1990-10-16	1997-01-15	John Lezdey	Behandlung von entzündungen
WO1992022320A1 (en)	1991-06-14	1992-12-23	Genentech, Inc.	C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4214215A1 (de)	1992-04-30	1993-11-04	Behringwerke Ag	Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen
US5686409A (en)	1994-04-08	1997-11-11	Research Corporation Technologies, Inc.	Antirestenosis protein
US5624946A (en)	1994-07-05	1997-04-29	Williams; James	Use of leflunomide to control and reverse chronic allograft rejection
US5939525A (en) *	1995-03-27	1999-08-17	Viron Therapeutics, Inc.	Methods of treating inflammation and compositions therefor
WO1997010006A1 (en)	1995-09-11	1997-03-20	The Governors Of The University Of Alberta	Method for inhibiting cell-mediated killing of target cells
GB9811854D0 (en)	1998-06-02	1998-07-29	Ciba Geigy Ag	Organic compounds
EP0982035B1 (en)	1998-08-18	2004-03-31	Panacea Biotec Limited	Cyclosporin composition comprising an hydrophilic carrier
US20020006901A1 (en)	1999-02-05	2002-01-17	Aldo T. Iacono	Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
AU3729300A (en)	1999-03-10	2000-09-28	American Red Cross	Brain-associated inhibitor of tissue-type plasminogen activator
DE60020727T2 (de)	1999-10-27	2006-05-04	Robert London Zhong	Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
US6428308B1 (en)	1999-11-29	2002-08-06	Honeywell Inc.	Electronic fuel convertibility selection
WO2001039790A1 (en)	1999-12-02	2001-06-07	Viron Therapeutics, Inc.	Methods of treating inflammation and compositions therefor
AU2001291579B2 (en)	2000-09-29	2006-08-31	Viron Therapeutics Inc.	Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
WO2004039391A1 (en)	2002-11-01	2004-05-13	Lucas Alexandra R	Viral serpin regulation of inflamation
US7285530B2 (en)	2004-10-21	2007-10-23	Viron Therapeutics, Inc.	Use of SERP-1 as an antiplatelet agent

2000
- 2000-10-27 DE DE60020727T patent/DE60020727T2/de not_active Expired - Lifetime
- 2000-10-27 JP JP2001532796A patent/JP2003512436A/ja active Pending
- 2000-10-27 CA CA2385312A patent/CA2385312C/en not_active Expired - Fee Related
- 2000-10-27 AU AU11230/01A patent/AU1123001A/en not_active Abandoned
- 2000-10-27 ES ES00972507T patent/ES2243314T3/es not_active Expired - Lifetime
- 2000-10-27 WO PCT/CA2000/001279 patent/WO2001030379A2/en not_active Ceased
- 2000-10-27 PT PT00972507T patent/PT1223971E/pt unknown
- 2000-10-27 EP EP00972507A patent/EP1223971B1/en not_active Expired - Lifetime
- 2000-10-27 AT AT00972507T patent/ATE297217T1/de active
2003
- 2003-03-13 US US10/388,149 patent/US7514405B2/en not_active Expired - Fee Related
2009
- 2009-02-23 US US12/380,063 patent/US7906483B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7906483B2 (en)	2011-03-15
US7514405B2 (en)	2009-04-07
CA2385312C (en)	2012-02-07
ATE297217T1 (de)	2005-06-15
US20090221472A1 (en)	2009-09-03
ES2243314T3 (es)	2005-12-01
DE60020727D1 (de)	2005-07-14
EP1223971B1 (en)	2005-06-08
DE60020727T2 (de)	2006-05-04
WO2001030379A2 (en)	2001-05-03
CA2385312A1 (en)	2001-05-03
US20030171263A1 (en)	2003-09-11
EP1223971A2 (en)	2002-07-24
JP2003512436A (ja)	2003-04-02
AU1123001A (en)	2001-05-08
WO2001030379A3 (en)	2001-09-20

Similar Documents

Publication	Publication Date	Title
DE69713151D1 (de)	2002-07-11	Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
PT1223971E (pt)	2005-10-31	Composicoes e metodos para prevencao e tratamento da rejeicao de transplante
AR003410A1 (es)	1998-08-05	Composicion para reducir el crecimiento capilar en mamiferos y metodo para producir dicha composicion
ZA953358B (en)	1996-01-17	New pharmaceutical composition based on taxoids
FR2757521B1 (fr)	1999-01-29	Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
TR200100172T2 (tr)	2001-05-21	Oral katı doz formunda eprosartan içeren biyolojik bakımdan kuvvetlendirilmiş formülasyonlar
PL364359A1 (en)	2004-12-13	Treatment or prophylaxis of insulin-producing cell graft rejection
AU9157901A (en)	2002-04-08	Methods of treating inflammatory and immune reactions and compositions therefor
ES2055415T3 (es)	1994-08-16	S-adenosil-metionina para el tratamiento de pancreatitis y del inmunorechazo del trasplante de pancreas.
ES2187646T3 (es)	2003-06-16	Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes.
IL155788A (en)	2013-09-30	A highly purified ifn – β active and mannitol-containing preparation, a method to make an improved stability of ifn – β active, and a method to enhance the stability of ifn – β in biologically active formulation.
EA199800717A1 (ru)	1999-02-25	Способ лечения заболеваний млекопитающих и цвиттерионная композиция
NO2019032I1 (no)	2019-07-23	Treosulfan
ES2133152T3 (es)	1999-09-01	Composicion de tiotepa liofilizada estable.
AR022017A1 (es)	2002-09-04	Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica
MXPA05003616A (es)	2006-01-24	Composiciones que comprenden anfotericina b altamente purificada.
AU4565000A (en)	2000-11-21	Organic compounds
NZ237739A (en)	1993-09-27	Pharmaceutical composition of a complement inhibitor and an immunosuppressant with cyclosporin a-like activity, and its use
AR021810A1 (es)	2002-08-07	Antagonista receptor de quiomicina y ciclosporina en terapia combinada
NO20030475L (no)	2003-03-28	Ikke-peptid CCR1-reseptorantagonist i kombinasjon med syclosporin A for behandling av hjertetransplantatforkastning
MXPA04005097A (es)	2004-08-19	Composicion y metodo para tratar el rechazo cronico de aloinjertos.
UY24181A1 (es)	1996-03-20	Método para tratar un infarto de miocardio agudo con hirudina y ácido acetilsalicílico en pacientes no sometidos a tratamiento trombolítico
AR027037A1 (es)	2003-03-12	Compusto y metodo para el tratamiento del dolor
SE0000234D0 (sv)	2000-01-26	Antifungal drug composition and drug delivery system